Andrew Hack

Andrew Hack, MD, PhD, is a seasoned investment professional in the life sciences sector, currently serving as a Partner at Bain Capital since March 2019, where the firm focuses on companies innovating in biopharmaceuticals and medical technologies. Prior to Bain Capital, Andrew was Chief Financial Officer at Editas Medicine, a leader in genomic medicine, from June 2015 to March 2019. Andrew's extensive experience includes roles as a Portfolio Manager at Millennium Management, an Analyst at HealthCor Management and Carlyle-Blue Wave Partners, and a Principal at MPM Capital. Earlier, Andrew held positions as a Biotechnology Analyst at Bank of America and Rodman & Renshaw, and Director of Life Sciences at Reify Corporation. Andrew obtained an M.D. and a Ph.D. in Molecular Genetics and Cell Biology from The University of Chicago Pritzker School of Medicine.